4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-22-061697
CIK 0001840574other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:00 PM ET
Size
6.9 KB
Accession
0001209191-22-061697
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-12-14−36,000→ 179,994 totalExercise: $2.87Exp: 2030-09-15→ Common Stock (36,000 underlying) - Exercise/Conversion
Common Stock
2022-12-14$2.87/sh+36,000$103,320→ 42,629 total
Footnotes (1)
- [F1]The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:00 PM ET
- Size
- 6.9 KB